A diabetes pill can lower your A1C and make your diabetes worse at the same time.

That sounds like a contradiction. It isn't. It's one of the most important things to understand about how type 2 diabetes is treated in this country — and one of the reasons so many patients feel like they're doing everything right and still getting sicker.

I'm Dr. Ford Brewer, a preventive medicine physician trained at Johns Hopkins, with over 40 years of clinical experience. I see this pattern in clinic all the time: a patient is on an older diabetes pill, their A1C looks fine on paper, and yet they're gaining weight, having scary low-blood-sugar episodes, and their underlying disease is getting worse. Meanwhile their family is watching them decline, wondering what's happening.

In this article, I'll walk you through which drugs do this, why the A1C alone can mislead you, what the safer options are, and the lifestyle move that lowers glucose without forcing more insulin into the system.

The Mechanism: Why Forcing Insulin Makes Insulin Resistance Worse

Most people think the problem in type 2 diabetes is high blood sugar. The real problem is insulin resistance. High blood sugar is the symptom.

Here's the chain. In type 2 diabetes, your cells stop responding properly to insulin. Your pancreas compensates by producing more insulin. For a while, that keeps glucose in range. Eventually the pancreas can't keep up, glucose rises, and you get diagnosed with diabetes.

Sulfonylureas — the older diabetes pills like glyburide, glipizide, and glimepiride — lower glucose by forcing your pancreas to make even more insulin, regardless of whether you're eating. They press harder on the same lever your body has been pressing on for years.

The result: glucose comes down, A1C improves, and three things get worse. Hypoglycemia risk rises because the drug forces insulin release even when you don't need it. Weight gain follows because insulin is a fat-storage signal, not just a glucose-lowering hormone. And the underlying insulin resistance often deepens, because added weight worsens it1.

Glucose is the symptom. Insulin resistance is the disease. A treatment that lowers the symptom while feeding the disease is not a win. It's a delay — and a costly one, because every year of worsening insulin resistance is another year of vascular damage, inflammation, and rising cardiovascular risk.

1. What Sulfonylureas Actually Do

*Best for: understanding the mechanism behind the side effects.*

Why It Matters

These drugs work by stimulating your pancreatic beta cells to secrete more insulin — whether or not your blood sugar is actually rising from a meal1. They don't fix the underlying problem. They press harder on the same lever your body has been straining against for years. That mechanism is why A1C improves. It's also why these drugs come with two real tradeoffs: more low blood sugar events, and more weight gain, compared with several newer options.

What Most People Miss

Sulfonylureas are cheap, decades old, and still widely prescribed because insurance covers them and they work fast on A1C. The newer options are usually better for the underlying disease — but the conversation often doesn't happen in a 7-minute appointment.

Question to Ask Your Clinician

*"Are we treating my glucose, or are we treating my insulin resistance? Which markers tell us whether the underlying disease is getting better or worse?"*

2. The A1C Problem: A "Good" Number Can Hide Real Danger

*Best for: understanding why the A1C alone is misleading.*

Why It Matters

A1C is an average glucose over about three months. It's useful. But averages hide what happens at the edges — and the edges are where the danger lives.

A patient on a sulfonylurea can have wild glucose swings: high spikes after meals, dangerous drops between them, overcorrections in both directions. The average can look fine. The day-to-day experience is anything but.

What Most People Miss

Your A1C tells you the midpoint. It doesn't tell you whether you're crashing at 3 a.m. or spiking after dinner. Real-world safety depends on what's happening at the edges, not the average. CGM (continuous glucose monitoring) shows the full picture — spikes, drops, time-in-range — in a way A1C can't.

Question to Ask Your Clinician

*"Can we use a continuous glucose monitor for a couple of weeks to see my actual glucose patterns — the spikes and the lows — instead of just my A1C number?"*

3. Hypoglycemia: The Underappreciated Risk

*Best for: recognizing the real-world danger of low blood sugar.*

Why It Matters

Low blood sugar isn't just feeling shaky. It progresses — sweating and lightheadedness give way to confusion, impaired coordination, falls, loss of consciousness. In older adults it sends people to the emergency room. It causes hip fractures. It causes car accidents. All sulfonylureas can cause hypoglycemia, and the risk goes up with inconsistent meals and reduced kidney or liver function — which is most older adults1.

What Most People Miss

The patients most likely to be on these drugs — older, often with some kidney decline, often with irregular eating patterns — are exactly the patients at highest risk for the worst outcomes when they go low. One bad episode while driving, while alone, or while on stairs can be life-altering for everyone in the family.

Question to Ask Your Clinician

*"Given my age, kidney function, and how I actually eat, what is my real-world risk of hypoglycemia on this medication?"*

4. The Metabolism Trap: Why More Insulin Means Worse Disease

*Best for: understanding why weight gain on this medication is a warning sign.*

Why It Matters

Insulin doesn't just lower glucose. Insulin is a fat-storage signal. When your medication pushes insulin higher than your body would naturally choose, three things happen:

  • Fat burning slows down.
  • Fat storage speeds up.
  • Appetite and carb cravings can intensify.

Medical references describe weight gain — often several kilograms — as a common effect of sulfonylureas, and note that this added weight may worsen insulin resistance over time1. Read that again. The drug treating your diabetes can make the underlying disease worse.

What Most People Miss

Patients on this medication often feel stuck. They're eating less. They're moving more. Their A1C looks better. And they keep gaining weight while their insulin resistance quietly deepens. The number on paper looks fine. The disease underneath isn't.

Question to Ask Your Clinician

*"My A1C is improving but I'm gaining weight on this drug. Is the underlying disease getting better or worse, and what markers would tell us?"*

5. Safer Options That Work With Your Metabolism, Not Against It

*Best for: knowing what to ask about as alternatives.*

Why It Matters

Diabetes treatment has to be individualized. Cost, kidney function, other conditions, and personal goals all matter. But for many patients, options exist that lower glucose without forcing the pancreas to overproduce insulin — and several deliver cardiovascular benefits beyond glucose control.

Metformin (typically first-line)

Metformin lowers glucose mostly by improving insulin sensitivity and reducing how much glucose your liver pumps out. It carries a low risk of hypoglycemia when used alone, and it's generally weight-neutral. Many references describe it as the first-line option because of efficacy, safety, and tolerability1. It works with your metabolism rather than against it.

SGLT2 inhibitors (cardiovascular and heart failure benefits)

SGLT2 inhibitors lower glucose by causing your kidneys to excrete some glucose in the urine — a completely different mechanism than forcing insulin. Research has shown evidence consistent with reduced heart failure hospitalization and reduced cardiovascular death in high-risk type 2 diabetes patients2. These aren't just glucose drugs. They're cardiovascular drugs that also lower glucose.

GLP-1 receptor agonists (metabolic and cardiovascular benefits)

GLP-1 receptor agonists improve glycemic control and often support weight loss — the opposite of what sulfonylureas do. Research has reported reductions in major adverse cardiovascular events and improvements in kidney-related outcomes3. For patients with insulin resistance, weight gain, and rising cardiovascular risk, this class is often a meaningful upgrade.

Important Note

These therapies aren't right for everyone. Side effects, contraindications, cost, and individual goals all matter. But if you're on a sulfonylurea and you're experiencing hypoglycemia or persistent weight gain, that's a reasonable trigger to revisit the plan with your prescriber.

Question to Ask Your Clinician

*"Are there alternatives to my current diabetes pill that would lower my glucose without forcing more insulin — and would any of them also reduce my cardiovascular risk?"*

6. The Lifestyle Lever That Lowers Glucose Without Forcing Insulin

*Best for: a no-cost tool that addresses the underlying disease.*

Why It Matters

Here's a tool you can use today that costs nothing and carries no risk of hypoglycemia: walk after meals. When you contract your leg muscles, those muscles pull glucose out of your bloodstream and into the cells — without needing extra insulin to do it. A systematic review concluded that post-meal exercise reduces post-meal glucose in people with type 2 diabetes, with the size of the effect depending on duration and intensity4.

A 10- to 15-minute walk after your largest meals of the day will meaningfully blunt the glucose spike for most people. It's not optional in addition to medication. It's a foundational tool that should be in place before adding more drugs.

What Most People Miss

If you're already on a sulfonylurea and you start cutting carbs and walking after meals, you can drop too low. Pairing strong lifestyle changes with an insulin-forcing drug increases the chance of overshooting into hypoglycemia. That's another reason to have the medication conversation with your clinician — your lifestyle improvements may have outgrown your prescription.

Question to Ask Your Clinician

*"As I improve my diet and activity, how will we adjust my medication so I don't end up overshooting into low blood sugar?"*

What Standard Care Misses (And the Testing That Actually Helps)

Standard diabetes care watches A1C and fasting glucose. Those numbers tell you whether you have diabetes and whether the average is moving. They don't tell you what's actually happening — the insulin patterns, the post-meal spikes, the vascular damage already underway.

This is a structural limitation of primary care, not a failing of individual physicians. The standard panel and the 7-minute appointment weren't built for this work.

The testing that actually helps:

  • OGTT/IR — oral glucose tolerance test with insulin response. Catches after-meal insulin problems that fasting tests miss entirely. This is the test that shows whether your insulin response is the actual problem.
  • CGM — continuous glucose monitoring. Shows real-world blood sugar patterns across meals, sleep, and stress. Reveals the spikes and lows your A1C is hiding.
  • Lipid fractionation, including ApoB and small-particle LDL (sdLDL) — directly counts the artery-damaging particles. Standard LDL is an estimate.
  • hsCRP, Lp-PLA2, MPO — inflammation markers that predict plaque rupture.
  • CIMT and coronary calcium scoring (CAC) — direct imaging of the artery wall and calcified plaque burden. Diabetes accelerates cardiovascular disease silently — these tests show what's already there.

The Bottom Line

A better A1C from forcing more insulin is not better diabetes control. It's a better-looking number sitting on top of a worse disease.

A practical recap:

  • Sulfonylureas lower glucose by forcing insulin release — with real risks of hypoglycemia and weight gain.
  • A1C is an average. It can look fine while glucose swings dangerously at the edges.
  • Weight gain from a diabetes drug is a signal that the underlying disease may be worsening.
  • Metformin, SGLT2 inhibitors, and GLP-1 receptor agonists work with your metabolism — some also reduce cardiovascular risk.
  • A 10- to 15-minute walk after meals lowers glucose without forcing more insulin.

The goal isn't to scare you off your medication. The goal is to make sure your treatment is actually treating your disease — because the people counting on you deserve a healthier you, not just a better-looking lab report.

Frequently Asked Questions

Quick answers to the questions that come up most often around this topic.

Are sulfonylureas safe for treating type 2 diabetes?

They lower glucose effectively, but they carry meaningful risks — especially hypoglycemia and weight gain — that newer medications often avoid. Sulfonylureas can still be the right choice for some patients, particularly when cost is the deciding factor. But if you're on one and experiencing low blood sugar episodes or steady weight gain, it's worth having a conversation with your prescriber about whether a different class would treat your disease more effectively.

Why does my A1C look good but I still feel terrible?

Because A1C is an average. A person can have wild glucose swings — high spikes after meals, dangerous drops between them — and still produce a "better" average number. If you feel shaky, foggy, or exhausted while your A1C looks fine, you're probably experiencing glucose variability the test isn't capturing. Ask your clinician about a CGM to see your actual patterns instead of just the three-month average.

Can a diabetes medication actually make diabetes worse?

Indirectly, yes. Sulfonylureas commonly cause weight gain, and added weight typically worsens insulin resistance — the underlying driver of type 2 diabetes. So you can end up with a better A1C and worsening underlying disease at the same time. The number on paper looks better while the disease underneath gets worse. Glucose-lowering alone is not the same as treating diabetes.

Why does insulin cause weight gain?

Insulin is a fat-storage signal as well as a glucose-lowering hormone. When medication pushes your insulin levels higher than your body would otherwise choose, fat burning slows, fat storage speeds up, and appetite and carb cravings often increase. That's why patients on sulfonylureas frequently gain weight even when they're trying to lose it. The drug is working against the metabolic outcome you actually want.

My doctor said my A1C looks fine. Should I still ask for more testing?

Yes. A1C measures average glucose, not insulin patterns or cardiovascular damage. The advanced testing that catches what A1C misses: OGTT/IR (oral glucose tolerance test with insulin response) to see your actual insulin response, CGM to see real-world glucose patterns, ApoB for artery-damaging particles, hsCRP for inflammation, and CIMT or coronary calcium scoring for direct imaging. These reveal what's actually happening, not just the average.

What is the safest medication for type 2 diabetes?

Metformin is typically considered first-line because of its efficacy, low hypoglycemia risk when used alone, and weight-neutral profile. SGLT2 inhibitors and GLP-1 receptor agonists are also strong options for many patients — several have demonstrated cardiovascular and kidney benefits beyond glucose control. The right choice depends on your kidney function, other conditions, and personal goals, so this is a decision to make with your clinician based on your full picture.

Should I walk before or after meals to lower blood sugar?

After meals. When your leg muscles contract, they pull glucose directly out of your bloodstream without needing extra insulin to do it. A systematic review found that post-meal exercise reduces post-meal glucose in people with type 2 diabetes, with the effect influenced by duration and intensity. A 10- to 15-minute walk within an hour after your largest meals will meaningfully blunt the glucose spike for most people.

Can lifestyle changes replace diabetes medication?

For some patients, yes. For others, they reduce the dose needed. Diet changes and consistent post-meal movement directly improve insulin sensitivity — the underlying problem in type 2 diabetes — while medications mostly address the symptom. That said, don't change or stop your prescription on your own. Pairing strong lifestyle changes with a sulfonylurea can push you into dangerous lows. Coordinate every change with your prescriber.

How PrevMed Helps

If you're managing type 2 diabetes — or watching your A1C creep up while your doctor tells you to "keep an eye on it" — you need more than the standard panel. The fasting glucose and A1C your annual physical runs were built to catch disease. They weren't built to catch the insulin resistance damaging your arteries years before diabetes shows up, or to tell you whether your current medication is treating the disease or just the number.

The PrevMed testing protocol catches what the standard panel misses. OGTT/IR shows your real insulin response. CGM shows your actual day-to-day patterns. Lipid fractionation with ApoB, hsCRP, and direct imaging like CIMT and CAC show whether your vascular system is already paying the price.

To see where you actually stand, take the PrevMed Heart Attack Prevention Assessment. The people who depend on you deserve a real answer about what's happening in your body — not just a number on a lab report.

Educational disclaimer: *This article is for educational purposes only and does not constitute medical advice. Decisions about diabetes medication, dosing, or substitution should be made with your clinician based on your individual risk, kidney and liver function, and overall health. Do not stop or change any prescription without speaking to your prescriber.*

References

  1. MSD Manual Professional Edition. "Medications for Diabetes Mellitus Treatment" (sulfonylureas mechanism, hypoglycemia risk, weight gain; metformin first-line). https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/diabetes-mellitus-and-hypoglycemia/medications-for-diabetes-mellitus-treatment
  2. PubMed review summarizing empagliflozin cardiovascular outcomes (reduced heart failure hospitalization and cardiovascular death in high-risk type 2 diabetes). https://pubmed.ncbi.nlm.nih.gov/34132492/
  3. PubMed review summarizing liraglutide cardiovascular outcomes (reductions in major adverse cardiovascular events and improvements in nephropathy outcomes). https://pubmed.ncbi.nlm.nih.gov/32618386/
  4. Systematic review: postprandial exercise reduces postprandial glucose in type 2 diabetes (effect influenced by duration and intensity). https://pubmed.ncbi.nlm.nih.gov/29396781/

Additional reading

This article is for educational purposes and isn’t medical advice. Talk to a clinician about decisions specific to your health.